GPS-2: A Protein Implicated in Diabetes and Neurodegenerative Diseases

Target Name: GPS2

NCBI ID: G2874

GPS2

Other Name(s): GPS-2 | GPS2_HUMAN | AMF-1 | G protein pathway suppressor 2

GPS-2: A Protein Implicated in Diabetes and Neurodegenerative Diseases

GPS-2, also known as GLUT-1, is a protein that is expressed in various tissues throughout the body. It is a member of the GLUT family, which includes the glucose transporter GLUT-2 and GLUT-4. GLUT-1 is predominantly expressed in the brain and is involved in the transport of glucose into the cell.

The potential drug targets for GPS-2 are numerous, and its research is being conducted in various fields, including neuroscience, endocrinology, and diabetes. One of the main focuses of research on GPS-2 is its role as a drug target for the treatment of diabetes.

A growing body of evidence has shown that GLUT-1 is involved in the regulation of insulin sensitivity and glucose metabolism. It has been shown to play a key role in the uptake and storage of glucose into the cell, as well as in the glucose-6-phosphate (G6P) return cycle. GLUT-1 has also been shown to play a role in the regulation of neural stem cell proliferation and in the development of neurodegenerative diseases.

In addition to its potential therapeutic applications, GPS-2 is also a potential biomarker for the diagnosis and monitoring of diabetes. The ability to measure the level of GLUT-1 in the bloodstream has been shown to be an accurate and reliable method of assessing diabetes status. This is because GLUT-1 is highly expressed in the body and is not regulated by insulin, which makes it a valuable target for the diagnosis and treatment of diabetes.

The research on GPS-2 is still in its infancy, and much more work is needed to fully understand its role in the regulation of glucose metabolism and its potential as a drug target or biomarker. However, the potential implications of GPS-2 research are vast and varied.

One of the main goals of research on GPS-2 is to develop new treatments for diabetes that target this protein. This could include drugs that modulate GLUT-1 function, such as inhibitors of GLUT-1 function that would decrease the uptake and storage of glucose into the cell. Alternatively, researchers could target GLUT-1 directly to increase its expression or activity, such as through the use of RNA interference or gene editing techniques.

Another potential application of GPS-2 research is its potential as a biomarker for the diagnosis and monitoring of diabetes. The ability to measure the level of GLUT-1 in the bloodstream makes it an attractive target for diagnostic tests. For example, researchers could use GLUT-1 levels as a marker for the diagnosis of diabetes, or as a marker for monitoring the effectiveness of different treatments.

In addition to its potential therapeutic and diagnostic applications, GPS-2 is also an important player in the regulation of glucose metabolism. Its role in the regulation of neural stem cell proliferation and in the development of neurodegenerative diseases suggests that it plays a key role in the development and progression of these diseases.

Overall, GPS-2 is a protein that has significant implications for our understanding of glucose metabolism and the regulation of neural stem cell proliferation. Further research is needed to fully understand its role in these processes and to develop new treatments for diabetes. However, the potential implications of GPS-2 research are vast and varied, and it is an important area of research that should be continued and explored further.

Protein Name: G Protein Pathway Suppressor 2

Functions: Key regulator of inflammation, lipid metabolism and mitochondrion homeostasis that acts by inhibiting the activity of the ubiquitin-conjugating enzyme UBE2N/Ubc13, thereby inhibiting 'Lys-63'-linked ubiquitination (By similarity). In the nucleus, can both acts as a corepressor and coactivator of transcription, depending on the context (PubMed:24943844). Acts as a transcription coactivator in adipocytes by promoting the recruitment of PPARG to promoters: acts by inhibiting the activity of the ubiquitin-conjugating enzyme UBE2N/Ubc13, leading to stabilization of KDM4A and subsequent histone H3 'Lys-9' (H3K9) demethylation (By similarity). Promotes cholesterol efflux by acting as a transcription coactivator (PubMed:19481530). Acts as a regulator of B-cell development by inhibiting UBE2N/Ubc13, thereby restricting the activation of Toll-like receptors (TLRs) and B-cell antigen receptors (BCRs) signaling pathways (By similarity). Acts as a key mediator of mitochondrial stress response: in response to mitochondrial depolarization, relocates from the mitochondria to the nucleus following desumoylation and specifically promotes expression of nuclear-encoded mitochondrial genes (PubMed:29499132). Promotes transcription of nuclear-encoded mitochondrial genes by inhibiting UBE2N/Ubc13 (PubMed:29499132). Can also act as a corepressor as part of the N-Cor repressor complex by repressing active PPARG (PubMed:19858209, PubMed:24943844). Plays an anti-inflammatory role in macrophages and is required for insulin sensitivity by acting as a corepressor (By similarity). Plays an anti-inflammatory role during the hepatic acute phase response by interacting with sumoylated NR1H2 and NR5A2 proteins, thereby preventing N-Cor corepressor complex dissociation (PubMed:20159957). In the cytosol, also plays a non-transcriptional role by regulating insulin signaling and pro-inflammatory pathways (By similarity). In the cytoplasm, acts as a negative regulator of inflammation by inhibiting the pro-inflammatory TNF-alpha pathway; acts by repressing UBE2N/Ubc13 activity (By similarity). In the cytoplasm of adipocytes, restricts the activation of insulin signaling via inhibition of UBE2N/Ubc13-mediated ubiquitination of AKT (By similarity). Able to suppress G-protein- and mitogen-activated protein kinase-mediated signal transduction (PubMed:8943324). Acts as a tumor-suppressor in liposarcoma (PubMed:27460081)

The "GPS2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GPS2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets